Global and Regional NewBorn Screening

NewBorn Screening Comprehensive Study by Type (Instruments {Newborn Disorder Screening Instruments, Newborn Hearing Screening Instruments (Hearing Screening Devices and Hearing Screening Accessories) and Pulse Oximeters}, Reagents and Assay Kits), Application (Hospitals, Clinics, Other), Technology (Tandem Mass Spectrometry, Pulse Oximetry Screening Technology, Immunoassays and Enzymatic Assays, DNA-Based Assays, Electrophoresis, Hearing Screen Technology, Others), Test (Dry Blood Spot Test, CCHD Test, Hearing Screen Test) Players and Region - Global Market Outlook to 2026

NewBorn Screening Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is NewBorn Screening Market?

The newborn screening is the practice of testing all babies on their first day of life for certain disorders and conditions that can hinder their normal development most of which are genetic. This testing is required in every state and it is performed before the baby leaves the hospital. The conditions included in newborn screening can cause serious health problems starting in infancy or childhood such as sickle cell disease, galactosemia, PKU etc. Screening helps to start treatment before serious problems can occur or become permanent.

The market study is being classified by Type (Instruments {Newborn Disorder Screening Instruments, Newborn Hearing Screening Instruments (Hearing Screening Devices and Hearing Screening Accessories) and Pulse Oximeters} and Reagents and Assay Kits), by Application (Hospitals, Clinics and Other) and major geographies with country level break-up.

AB SCIEX (United States), Agilent Technologies (United States), PerkinElmer Inc. (United States), Bio-Rad Laboratories (United States), Covidien PLC (Ireland), GE Life Sciences (United Kingdom), Masimo Corporation (United States), Natus Medical Incorporated (United States), Trivitron Healthcare (India) and Waters Corporation (United States) are some of the key players profiled in the study.

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global NewBorn Screening market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global NewBorn Screening market by Type, Application and Region.

On the basis of geography, the market of NewBorn Screening has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rising Prevalence of Congenital Disorders Responsible For Mental Retardation
  • Increasing Awareness of the Screening Benefits among People

Market Trend
  • Technological Innovations and Advancements

Restraints
  • Lack of Specialized Infrastructure and Socio-Economic Barriers in Emerging Countries

Opportunities
  • Rising Neonatal Population
  • Large Pool of Patient in Emerging Countries Such As China and India

Challenges
  • High Cost of Automation Technology
  • Lack of Unified Newborn Screening Policies Worldwide





Key Target Audience
Newborn Screening Equipment Manufacturers, Raw Material Suppliers/ Buyers, Distributors, Government Body & Associations and End-user

Report Objectives / Segmentation Covered

By Type
  • Instruments {Newborn Disorder Screening Instruments, Newborn Hearing Screening Instruments (Hearing Screening Devices and Hearing Screening Accessories) and Pulse Oximeters}
  • Reagents and Assay Kits
By Application
  • Hospitals
  • Clinics
  • Other
By Technology
  • Tandem Mass Spectrometry
  • Pulse Oximetry Screening Technology
  • Immunoassays and Enzymatic Assays
  • DNA-Based Assays
  • Electrophoresis
  • Hearing Screen Technology
  • Others

By Test
  • Dry Blood Spot Test
  • CCHD Test
  • Hearing Screen Test

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Congenital Disorders Responsible For Mental Retardation
      • 3.2.2. Increasing Awareness of the Screening Benefits among People
    • 3.3. Market Challenges
      • 3.3.1. High Cost of Automation Technology
      • 3.3.2. Lack of Unified Newborn Screening Policies Worldwide
    • 3.4. Market Trends
      • 3.4.1. Technological Innovations and Advancements
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global NewBorn Screening, by Type, Application, Technology, Test and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global NewBorn Screening (Value)
      • 5.2.1. Global NewBorn Screening by: Type (Value)
        • 5.2.1.1. Instruments {Newborn Disorder Screening Instruments, Newborn Hearing Screening Instruments (Hearing Screening Devices and Hearing Screening Accessories) and Pulse Oximeters}
        • 5.2.1.2. Reagents and Assay Kits
      • 5.2.2. Global NewBorn Screening by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Other
      • 5.2.3. Global NewBorn Screening by: Technology (Value)
        • 5.2.3.1. Tandem Mass Spectrometry
        • 5.2.3.2. Pulse Oximetry Screening Technology
        • 5.2.3.3. Immunoassays and Enzymatic Assays
        • 5.2.3.4. DNA-Based Assays
        • 5.2.3.5. Electrophoresis
        • 5.2.3.6. Hearing Screen Technology
        • 5.2.3.7. Others
      • 5.2.4. Global NewBorn Screening by: Test (Value)
        • 5.2.4.1. Dry Blood Spot Test
        • 5.2.4.2. CCHD Test
        • 5.2.4.3. Hearing Screen Test
      • 5.2.5. Global NewBorn Screening Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. NewBorn Screening: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AB SCIEX (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Agilent Technologies (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. PerkinElmer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bio-Rad Laboratories (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Covidien PLC (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GE Life Sciences (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Masimo Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Natus Medical Incorporated (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Trivitron Healthcare (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Waters Corporation (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global NewBorn Screening Sale, by Type, Application, Technology, Test and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global NewBorn Screening (Value)
      • 7.2.1. Global NewBorn Screening by: Type (Value)
        • 7.2.1.1. Instruments {Newborn Disorder Screening Instruments, Newborn Hearing Screening Instruments (Hearing Screening Devices and Hearing Screening Accessories) and Pulse Oximeters}
        • 7.2.1.2. Reagents and Assay Kits
      • 7.2.2. Global NewBorn Screening by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Other
      • 7.2.3. Global NewBorn Screening by: Technology (Value)
        • 7.2.3.1. Tandem Mass Spectrometry
        • 7.2.3.2. Pulse Oximetry Screening Technology
        • 7.2.3.3. Immunoassays and Enzymatic Assays
        • 7.2.3.4. DNA-Based Assays
        • 7.2.3.5. Electrophoresis
        • 7.2.3.6. Hearing Screen Technology
        • 7.2.3.7. Others
      • 7.2.4. Global NewBorn Screening by: Test (Value)
        • 7.2.4.1. Dry Blood Spot Test
        • 7.2.4.2. CCHD Test
        • 7.2.4.3. Hearing Screen Test
      • 7.2.5. Global NewBorn Screening Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. NewBorn Screening: by Type(USD Million)
  • Table 2. NewBorn Screening Instruments {Newborn Disorder Screening Instruments, Newborn Hearing Screening Instruments (Hearing Screening Devices and Hearing Screening Accessories) and Pulse Oximeters} , by Region USD Million (2015-2020)
  • Table 3. NewBorn Screening Reagents and Assay Kits , by Region USD Million (2015-2020)
  • Table 4. NewBorn Screening: by Application(USD Million)
  • Table 5. NewBorn Screening Hospitals , by Region USD Million (2015-2020)
  • Table 6. NewBorn Screening Clinics , by Region USD Million (2015-2020)
  • Table 7. NewBorn Screening Other , by Region USD Million (2015-2020)
  • Table 8. NewBorn Screening: by Technology(USD Million)
  • Table 9. NewBorn Screening Tandem Mass Spectrometry , by Region USD Million (2015-2020)
  • Table 10. NewBorn Screening Pulse Oximetry Screening Technology , by Region USD Million (2015-2020)
  • Table 11. NewBorn Screening Immunoassays and Enzymatic Assays , by Region USD Million (2015-2020)
  • Table 12. NewBorn Screening DNA-Based Assays , by Region USD Million (2015-2020)
  • Table 13. NewBorn Screening Electrophoresis , by Region USD Million (2015-2020)
  • Table 14. NewBorn Screening Hearing Screen Technology , by Region USD Million (2015-2020)
  • Table 15. NewBorn Screening Others , by Region USD Million (2015-2020)
  • Table 16. NewBorn Screening: by Test(USD Million)
  • Table 17. NewBorn Screening Dry Blood Spot Test , by Region USD Million (2015-2020)
  • Table 18. NewBorn Screening CCHD Test , by Region USD Million (2015-2020)
  • Table 19. NewBorn Screening Hearing Screen Test , by Region USD Million (2015-2020)
  • Table 20. South America NewBorn Screening, by Country USD Million (2015-2020)
  • Table 21. South America NewBorn Screening, by Type USD Million (2015-2020)
  • Table 22. South America NewBorn Screening, by Application USD Million (2015-2020)
  • Table 23. South America NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 24. South America NewBorn Screening, by Test USD Million (2015-2020)
  • Table 25. Brazil NewBorn Screening, by Type USD Million (2015-2020)
  • Table 26. Brazil NewBorn Screening, by Application USD Million (2015-2020)
  • Table 27. Brazil NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 28. Brazil NewBorn Screening, by Test USD Million (2015-2020)
  • Table 29. Argentina NewBorn Screening, by Type USD Million (2015-2020)
  • Table 30. Argentina NewBorn Screening, by Application USD Million (2015-2020)
  • Table 31. Argentina NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 32. Argentina NewBorn Screening, by Test USD Million (2015-2020)
  • Table 33. Rest of South America NewBorn Screening, by Type USD Million (2015-2020)
  • Table 34. Rest of South America NewBorn Screening, by Application USD Million (2015-2020)
  • Table 35. Rest of South America NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 36. Rest of South America NewBorn Screening, by Test USD Million (2015-2020)
  • Table 37. Asia Pacific NewBorn Screening, by Country USD Million (2015-2020)
  • Table 38. Asia Pacific NewBorn Screening, by Type USD Million (2015-2020)
  • Table 39. Asia Pacific NewBorn Screening, by Application USD Million (2015-2020)
  • Table 40. Asia Pacific NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 41. Asia Pacific NewBorn Screening, by Test USD Million (2015-2020)
  • Table 42. China NewBorn Screening, by Type USD Million (2015-2020)
  • Table 43. China NewBorn Screening, by Application USD Million (2015-2020)
  • Table 44. China NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 45. China NewBorn Screening, by Test USD Million (2015-2020)
  • Table 46. Japan NewBorn Screening, by Type USD Million (2015-2020)
  • Table 47. Japan NewBorn Screening, by Application USD Million (2015-2020)
  • Table 48. Japan NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 49. Japan NewBorn Screening, by Test USD Million (2015-2020)
  • Table 50. India NewBorn Screening, by Type USD Million (2015-2020)
  • Table 51. India NewBorn Screening, by Application USD Million (2015-2020)
  • Table 52. India NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 53. India NewBorn Screening, by Test USD Million (2015-2020)
  • Table 54. South Korea NewBorn Screening, by Type USD Million (2015-2020)
  • Table 55. South Korea NewBorn Screening, by Application USD Million (2015-2020)
  • Table 56. South Korea NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 57. South Korea NewBorn Screening, by Test USD Million (2015-2020)
  • Table 58. Taiwan NewBorn Screening, by Type USD Million (2015-2020)
  • Table 59. Taiwan NewBorn Screening, by Application USD Million (2015-2020)
  • Table 60. Taiwan NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 61. Taiwan NewBorn Screening, by Test USD Million (2015-2020)
  • Table 62. Australia NewBorn Screening, by Type USD Million (2015-2020)
  • Table 63. Australia NewBorn Screening, by Application USD Million (2015-2020)
  • Table 64. Australia NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 65. Australia NewBorn Screening, by Test USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific NewBorn Screening, by Type USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific NewBorn Screening, by Application USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific NewBorn Screening, by Test USD Million (2015-2020)
  • Table 70. Europe NewBorn Screening, by Country USD Million (2015-2020)
  • Table 71. Europe NewBorn Screening, by Type USD Million (2015-2020)
  • Table 72. Europe NewBorn Screening, by Application USD Million (2015-2020)
  • Table 73. Europe NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 74. Europe NewBorn Screening, by Test USD Million (2015-2020)
  • Table 75. Germany NewBorn Screening, by Type USD Million (2015-2020)
  • Table 76. Germany NewBorn Screening, by Application USD Million (2015-2020)
  • Table 77. Germany NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 78. Germany NewBorn Screening, by Test USD Million (2015-2020)
  • Table 79. France NewBorn Screening, by Type USD Million (2015-2020)
  • Table 80. France NewBorn Screening, by Application USD Million (2015-2020)
  • Table 81. France NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 82. France NewBorn Screening, by Test USD Million (2015-2020)
  • Table 83. Italy NewBorn Screening, by Type USD Million (2015-2020)
  • Table 84. Italy NewBorn Screening, by Application USD Million (2015-2020)
  • Table 85. Italy NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 86. Italy NewBorn Screening, by Test USD Million (2015-2020)
  • Table 87. United Kingdom NewBorn Screening, by Type USD Million (2015-2020)
  • Table 88. United Kingdom NewBorn Screening, by Application USD Million (2015-2020)
  • Table 89. United Kingdom NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 90. United Kingdom NewBorn Screening, by Test USD Million (2015-2020)
  • Table 91. Netherlands NewBorn Screening, by Type USD Million (2015-2020)
  • Table 92. Netherlands NewBorn Screening, by Application USD Million (2015-2020)
  • Table 93. Netherlands NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 94. Netherlands NewBorn Screening, by Test USD Million (2015-2020)
  • Table 95. Rest of Europe NewBorn Screening, by Type USD Million (2015-2020)
  • Table 96. Rest of Europe NewBorn Screening, by Application USD Million (2015-2020)
  • Table 97. Rest of Europe NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 98. Rest of Europe NewBorn Screening, by Test USD Million (2015-2020)
  • Table 99. MEA NewBorn Screening, by Country USD Million (2015-2020)
  • Table 100. MEA NewBorn Screening, by Type USD Million (2015-2020)
  • Table 101. MEA NewBorn Screening, by Application USD Million (2015-2020)
  • Table 102. MEA NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 103. MEA NewBorn Screening, by Test USD Million (2015-2020)
  • Table 104. Middle East NewBorn Screening, by Type USD Million (2015-2020)
  • Table 105. Middle East NewBorn Screening, by Application USD Million (2015-2020)
  • Table 106. Middle East NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 107. Middle East NewBorn Screening, by Test USD Million (2015-2020)
  • Table 108. Africa NewBorn Screening, by Type USD Million (2015-2020)
  • Table 109. Africa NewBorn Screening, by Application USD Million (2015-2020)
  • Table 110. Africa NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 111. Africa NewBorn Screening, by Test USD Million (2015-2020)
  • Table 112. North America NewBorn Screening, by Country USD Million (2015-2020)
  • Table 113. North America NewBorn Screening, by Type USD Million (2015-2020)
  • Table 114. North America NewBorn Screening, by Application USD Million (2015-2020)
  • Table 115. North America NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 116. North America NewBorn Screening, by Test USD Million (2015-2020)
  • Table 117. United States NewBorn Screening, by Type USD Million (2015-2020)
  • Table 118. United States NewBorn Screening, by Application USD Million (2015-2020)
  • Table 119. United States NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 120. United States NewBorn Screening, by Test USD Million (2015-2020)
  • Table 121. Canada NewBorn Screening, by Type USD Million (2015-2020)
  • Table 122. Canada NewBorn Screening, by Application USD Million (2015-2020)
  • Table 123. Canada NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 124. Canada NewBorn Screening, by Test USD Million (2015-2020)
  • Table 125. Mexico NewBorn Screening, by Type USD Million (2015-2020)
  • Table 126. Mexico NewBorn Screening, by Application USD Million (2015-2020)
  • Table 127. Mexico NewBorn Screening, by Technology USD Million (2015-2020)
  • Table 128. Mexico NewBorn Screening, by Test USD Million (2015-2020)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. NewBorn Screening: by Type(USD Million)
  • Table 140. NewBorn Screening Instruments {Newborn Disorder Screening Instruments, Newborn Hearing Screening Instruments (Hearing Screening Devices and Hearing Screening Accessories) and Pulse Oximeters} , by Region USD Million (2021-2026)
  • Table 141. NewBorn Screening Reagents and Assay Kits , by Region USD Million (2021-2026)
  • Table 142. NewBorn Screening: by Application(USD Million)
  • Table 143. NewBorn Screening Hospitals , by Region USD Million (2021-2026)
  • Table 144. NewBorn Screening Clinics , by Region USD Million (2021-2026)
  • Table 145. NewBorn Screening Other , by Region USD Million (2021-2026)
  • Table 146. NewBorn Screening: by Technology(USD Million)
  • Table 147. NewBorn Screening Tandem Mass Spectrometry , by Region USD Million (2021-2026)
  • Table 148. NewBorn Screening Pulse Oximetry Screening Technology , by Region USD Million (2021-2026)
  • Table 149. NewBorn Screening Immunoassays and Enzymatic Assays , by Region USD Million (2021-2026)
  • Table 150. NewBorn Screening DNA-Based Assays , by Region USD Million (2021-2026)
  • Table 151. NewBorn Screening Electrophoresis , by Region USD Million (2021-2026)
  • Table 152. NewBorn Screening Hearing Screen Technology , by Region USD Million (2021-2026)
  • Table 153. NewBorn Screening Others , by Region USD Million (2021-2026)
  • Table 154. NewBorn Screening: by Test(USD Million)
  • Table 155. NewBorn Screening Dry Blood Spot Test , by Region USD Million (2021-2026)
  • Table 156. NewBorn Screening CCHD Test , by Region USD Million (2021-2026)
  • Table 157. NewBorn Screening Hearing Screen Test , by Region USD Million (2021-2026)
  • Table 158. South America NewBorn Screening, by Country USD Million (2021-2026)
  • Table 159. South America NewBorn Screening, by Type USD Million (2021-2026)
  • Table 160. South America NewBorn Screening, by Application USD Million (2021-2026)
  • Table 161. South America NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 162. South America NewBorn Screening, by Test USD Million (2021-2026)
  • Table 163. Brazil NewBorn Screening, by Type USD Million (2021-2026)
  • Table 164. Brazil NewBorn Screening, by Application USD Million (2021-2026)
  • Table 165. Brazil NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 166. Brazil NewBorn Screening, by Test USD Million (2021-2026)
  • Table 167. Argentina NewBorn Screening, by Type USD Million (2021-2026)
  • Table 168. Argentina NewBorn Screening, by Application USD Million (2021-2026)
  • Table 169. Argentina NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 170. Argentina NewBorn Screening, by Test USD Million (2021-2026)
  • Table 171. Rest of South America NewBorn Screening, by Type USD Million (2021-2026)
  • Table 172. Rest of South America NewBorn Screening, by Application USD Million (2021-2026)
  • Table 173. Rest of South America NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 174. Rest of South America NewBorn Screening, by Test USD Million (2021-2026)
  • Table 175. Asia Pacific NewBorn Screening, by Country USD Million (2021-2026)
  • Table 176. Asia Pacific NewBorn Screening, by Type USD Million (2021-2026)
  • Table 177. Asia Pacific NewBorn Screening, by Application USD Million (2021-2026)
  • Table 178. Asia Pacific NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 179. Asia Pacific NewBorn Screening, by Test USD Million (2021-2026)
  • Table 180. China NewBorn Screening, by Type USD Million (2021-2026)
  • Table 181. China NewBorn Screening, by Application USD Million (2021-2026)
  • Table 182. China NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 183. China NewBorn Screening, by Test USD Million (2021-2026)
  • Table 184. Japan NewBorn Screening, by Type USD Million (2021-2026)
  • Table 185. Japan NewBorn Screening, by Application USD Million (2021-2026)
  • Table 186. Japan NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 187. Japan NewBorn Screening, by Test USD Million (2021-2026)
  • Table 188. India NewBorn Screening, by Type USD Million (2021-2026)
  • Table 189. India NewBorn Screening, by Application USD Million (2021-2026)
  • Table 190. India NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 191. India NewBorn Screening, by Test USD Million (2021-2026)
  • Table 192. South Korea NewBorn Screening, by Type USD Million (2021-2026)
  • Table 193. South Korea NewBorn Screening, by Application USD Million (2021-2026)
  • Table 194. South Korea NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 195. South Korea NewBorn Screening, by Test USD Million (2021-2026)
  • Table 196. Taiwan NewBorn Screening, by Type USD Million (2021-2026)
  • Table 197. Taiwan NewBorn Screening, by Application USD Million (2021-2026)
  • Table 198. Taiwan NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 199. Taiwan NewBorn Screening, by Test USD Million (2021-2026)
  • Table 200. Australia NewBorn Screening, by Type USD Million (2021-2026)
  • Table 201. Australia NewBorn Screening, by Application USD Million (2021-2026)
  • Table 202. Australia NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 203. Australia NewBorn Screening, by Test USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific NewBorn Screening, by Type USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific NewBorn Screening, by Application USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific NewBorn Screening, by Test USD Million (2021-2026)
  • Table 208. Europe NewBorn Screening, by Country USD Million (2021-2026)
  • Table 209. Europe NewBorn Screening, by Type USD Million (2021-2026)
  • Table 210. Europe NewBorn Screening, by Application USD Million (2021-2026)
  • Table 211. Europe NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 212. Europe NewBorn Screening, by Test USD Million (2021-2026)
  • Table 213. Germany NewBorn Screening, by Type USD Million (2021-2026)
  • Table 214. Germany NewBorn Screening, by Application USD Million (2021-2026)
  • Table 215. Germany NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 216. Germany NewBorn Screening, by Test USD Million (2021-2026)
  • Table 217. France NewBorn Screening, by Type USD Million (2021-2026)
  • Table 218. France NewBorn Screening, by Application USD Million (2021-2026)
  • Table 219. France NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 220. France NewBorn Screening, by Test USD Million (2021-2026)
  • Table 221. Italy NewBorn Screening, by Type USD Million (2021-2026)
  • Table 222. Italy NewBorn Screening, by Application USD Million (2021-2026)
  • Table 223. Italy NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 224. Italy NewBorn Screening, by Test USD Million (2021-2026)
  • Table 225. United Kingdom NewBorn Screening, by Type USD Million (2021-2026)
  • Table 226. United Kingdom NewBorn Screening, by Application USD Million (2021-2026)
  • Table 227. United Kingdom NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 228. United Kingdom NewBorn Screening, by Test USD Million (2021-2026)
  • Table 229. Netherlands NewBorn Screening, by Type USD Million (2021-2026)
  • Table 230. Netherlands NewBorn Screening, by Application USD Million (2021-2026)
  • Table 231. Netherlands NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 232. Netherlands NewBorn Screening, by Test USD Million (2021-2026)
  • Table 233. Rest of Europe NewBorn Screening, by Type USD Million (2021-2026)
  • Table 234. Rest of Europe NewBorn Screening, by Application USD Million (2021-2026)
  • Table 235. Rest of Europe NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 236. Rest of Europe NewBorn Screening, by Test USD Million (2021-2026)
  • Table 237. MEA NewBorn Screening, by Country USD Million (2021-2026)
  • Table 238. MEA NewBorn Screening, by Type USD Million (2021-2026)
  • Table 239. MEA NewBorn Screening, by Application USD Million (2021-2026)
  • Table 240. MEA NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 241. MEA NewBorn Screening, by Test USD Million (2021-2026)
  • Table 242. Middle East NewBorn Screening, by Type USD Million (2021-2026)
  • Table 243. Middle East NewBorn Screening, by Application USD Million (2021-2026)
  • Table 244. Middle East NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 245. Middle East NewBorn Screening, by Test USD Million (2021-2026)
  • Table 246. Africa NewBorn Screening, by Type USD Million (2021-2026)
  • Table 247. Africa NewBorn Screening, by Application USD Million (2021-2026)
  • Table 248. Africa NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 249. Africa NewBorn Screening, by Test USD Million (2021-2026)
  • Table 250. North America NewBorn Screening, by Country USD Million (2021-2026)
  • Table 251. North America NewBorn Screening, by Type USD Million (2021-2026)
  • Table 252. North America NewBorn Screening, by Application USD Million (2021-2026)
  • Table 253. North America NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 254. North America NewBorn Screening, by Test USD Million (2021-2026)
  • Table 255. United States NewBorn Screening, by Type USD Million (2021-2026)
  • Table 256. United States NewBorn Screening, by Application USD Million (2021-2026)
  • Table 257. United States NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 258. United States NewBorn Screening, by Test USD Million (2021-2026)
  • Table 259. Canada NewBorn Screening, by Type USD Million (2021-2026)
  • Table 260. Canada NewBorn Screening, by Application USD Million (2021-2026)
  • Table 261. Canada NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 262. Canada NewBorn Screening, by Test USD Million (2021-2026)
  • Table 263. Mexico NewBorn Screening, by Type USD Million (2021-2026)
  • Table 264. Mexico NewBorn Screening, by Application USD Million (2021-2026)
  • Table 265. Mexico NewBorn Screening, by Technology USD Million (2021-2026)
  • Table 266. Mexico NewBorn Screening, by Test USD Million (2021-2026)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global NewBorn Screening: by Type USD Million (2015-2020)
  • Figure 5. Global NewBorn Screening: by Application USD Million (2015-2020)
  • Figure 6. Global NewBorn Screening: by Technology USD Million (2015-2020)
  • Figure 7. Global NewBorn Screening: by Test USD Million (2015-2020)
  • Figure 8. South America NewBorn Screening Share (%), by Country
  • Figure 9. Asia Pacific NewBorn Screening Share (%), by Country
  • Figure 10. Europe NewBorn Screening Share (%), by Country
  • Figure 11. MEA NewBorn Screening Share (%), by Country
  • Figure 12. North America NewBorn Screening Share (%), by Country
  • Figure 13. Global NewBorn Screening share by Players 2020 (%)
  • Figure 14. Global NewBorn Screening share by Players (Top 3) 2020(%)
  • Figure 15. Global NewBorn Screening share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. AB SCIEX (United States) Revenue, Net Income and Gross profit
  • Figure 18. AB SCIEX (United States) Revenue: by Geography 2020
  • Figure 19. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 20. Agilent Technologies (United States) Revenue: by Geography 2020
  • Figure 21. PerkinElmer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. PerkinElmer Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Bio-Rad Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 24. Bio-Rad Laboratories (United States) Revenue: by Geography 2020
  • Figure 25. Covidien PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 26. Covidien PLC (Ireland) Revenue: by Geography 2020
  • Figure 27. GE Life Sciences (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. GE Life Sciences (United Kingdom) Revenue: by Geography 2020
  • Figure 29. Masimo Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. Masimo Corporation (United States) Revenue: by Geography 2020
  • Figure 31. Natus Medical Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 32. Natus Medical Incorporated (United States) Revenue: by Geography 2020
  • Figure 33. Trivitron Healthcare (India) Revenue, Net Income and Gross profit
  • Figure 34. Trivitron Healthcare (India) Revenue: by Geography 2020
  • Figure 35. Waters Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 36. Waters Corporation (United States) Revenue: by Geography 2020
  • Figure 37. Global NewBorn Screening: by Type USD Million (2021-2026)
  • Figure 38. Global NewBorn Screening: by Application USD Million (2021-2026)
  • Figure 39. Global NewBorn Screening: by Technology USD Million (2021-2026)
  • Figure 40. Global NewBorn Screening: by Test USD Million (2021-2026)
  • Figure 41. South America NewBorn Screening Share (%), by Country
  • Figure 42. Asia Pacific NewBorn Screening Share (%), by Country
  • Figure 43. Europe NewBorn Screening Share (%), by Country
  • Figure 44. MEA NewBorn Screening Share (%), by Country
  • Figure 45. North America NewBorn Screening Share (%), by Country
List of companies from research coverage that are profiled in the study
  • AB SCIEX (United States)
  • Agilent Technologies (United States)
  • PerkinElmer Inc. (United States)
  • Bio-Rad Laboratories (United States)
  • Covidien PLC (Ireland)
  • GE Life Sciences (United Kingdom)
  • Masimo Corporation (United States)
  • Natus Medical Incorporated (United States)
  • Trivitron Healthcare (India)
  • Waters Corporation (United States)
Select User Access Type

Key Highlights of Report


Sep 2021 250 Pages 54 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global and Regional NewBorn Screening Quantitative research analysis
Global and Regional NewBorn Screening Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Rising Prevalence of Congenital Disorders Responsible For Mental Retardation " is seen as one of major growth factors of NewBorn Screening Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
United States will lead NewBorn Screening Market in coming years.

Know More About Global and Regional NewBorn Screening Report?

Have a Query? Click Here

Other Related Reports

Interventional Radiology Comprehensive Study by Type (X-ray, Computed Tomography, Magnetic Resonance Imaging (MRI), Ultrasound), Application (Oncology, Cardiology, Urology & Nephrology, Gastroenterol...
$ 3750
Wireless Health and Fitness Devices Comprehensive Study by Type (Wrist Strap Type Devices, Wearable Type Devices, Other), Application (Monitoring, Diagnosis), Sales Channel (Pharmacies, Online Channe...
$ 3750
Urinalysis Analyzers Comprehensive Study by Type (Semi-Automatic, Fully-Automatic), Application (Urinary Tract Infections, Kidney Diseases, Diabetes, Others), Sales (Online, Offline), End-User (Hospi...
$ 3350
Dental Imaging Comprehensive Study by Type (Extraoral Imaging, Intraoral Imaging, Others), Application (Diagnostic Applications, Therapeutic Applications, Cosmetic Applications, Forensic Applications...
$ 3500
Digital Pathology Comprehensive Study by Type (Whole Slide Imaging, Image Analysis Informatics, Information Management System Storage & Communication, Digital IVD Devices, Others (Telepathology)), Ap...
$ 3750
Nerve Monitoring System Comprehensive Study by Application (Neurosurgery, ENT Surgery, Spine Surgery, Cardiovascular Surgery, Other), Technology (EEG Technology, EMG Technology, EP Technology, ECOG T...
$ 3450